The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of dacomitinib for the frontline treatment of adult patients with metastatic non–small cell lung cancer with EGFR-activating mutations.
Original Article: Dacomitinib Approaches EU Approval for EGFR+ NSCLC